Abstract
Autism spectrum disorders (ASD) is a group of generalized neurodevelopmental disorders. Its main clinical features are social communication disorder and repetitive stereotyped behavioral interest. The abnormal structure and function of brain network is the basis of social dysfunction and stereotyped performance in patients with autism spectrum disorder. The number of patients diagnosed with ASD has increased year by year, but there is a lack of effective intervention and treatment. Oxytocin has been revealed to effectively improve social cognitive function and significantly improve the social information processing ability, empathy ability and social communication ability of ASD patients. The change of serotonin level also been reported affecting the development of brain and causes ASD-like behavioral abnormalities, such as anxiety, depression like behavior, stereotyped behavior. Present review will focus on the research progress of serotonin and oxytocin in the pathogenesis, brain circuit changes and treatment of autism. Revealing the regulatory effect and neural mechanism of serotonin and oxytocin on patients with ASD is not only conducive to a deeper comprehension of the pathogenesis of ASD, but also has vital clinical significance.
Introduction
Autism Spectrum Disorder (ASD) is a highly heterogeneous neurodevelopmental condition characterized by social communication deficits and restricted, repetitive behaviors. Despite its growing prevalence, the underlying neurobiological mechanisms—the "black box" between genetic mutations and clinical presentation—remain partially understood. This review synthesizes research on two key neuromodulators, oxytocin (OXT) and serotonin (5-HT), which serve as critical regulators of the neural circuits affected in ASD. By examining their roles in brain hubs like the amygdala, medial prefrontal cortex (mPFC), and striatum, we can better understand the biological drivers of autism-related behavior.
Methodology and Animal Models
Understanding the pathogenesis of ASD requires a multi-disciplinary approach, bridging human neuroimaging with genetic analysis and animal models. Researchers utilize various genetic models, such as Cntnap2, Shank3, and Mecp2 knockout mice, to simulate specific aspects of the disorder. These models allow for the investigation of how genetic disruptions lead to abnormal neuronal migration, asynchronous cortical discharge, and subsequent behavioral abnormalities like reduced social interaction or increased repetitive grooming.
Neurobiological Mechanisms of ASD Symptoms
A central hypothesis in ASD research is the "underconnectivity" of frontal-posterior brain regions, which may explain social cognitive impairments. Oxytocin acts as a "social key," modulating the amygdala-mPFC axis to reduce social anxiety and enhance the reward value of social stimuli. In contrast, serotonin signaling is heavily involved in early brain development and the regulation of repetitive behaviors. Specifically, elevated 5HT2A receptor signaling in the dorsomedial striatum has been identified as a primary driver of stereotyped behaviors, and its antagonism has shown potential in "rescuing" these behaviors in animal models.
Clinical Insights and Results
Clinical trials investigating intranasal oxytocin have shown mixed results. While short-term administration can increase eye contact and social brain activity, long-term trials have often failed to demonstrate significant improvement over placebos. Serotonin research presents a similar complexity; while many ASD patients exhibit hyperserotonemia (high blood serotonin), the central serotonin system is often malformed. Selective Serotonin Reuptake Inhibitors (SSRIs) have shown some efficacy in reducing compulsive behaviors in adults, but their use in children and during pregnancy remains a subject of intense debate due to potential developmental risks.
Conclusion and Future Directions
The future of ASD treatment lies in precision medicine, moving away from a one-size-fits-all approach toward interventions tailored to a patient's specific genetic and neurobiological profile. Emerging tools like human cortical organoids and single-cell sequencing will be vital in mapping how OXT and 5-HT influence early neuronal migration and circuit formation. Addressing the heterogeneity of ASD and the challenges of drug delivery across the blood-brain barrier remains the primary hurdle for developing the next generation of effective therapies.
Summary updated